Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
74 Results for "
BCL2L2
" in MedChemExpress (MCE) Product Catalog:
Products (74)
74 Results for "BCL2L2" in MCE Product Catalog:
Cat. No.: HY-N20627
CAS No.: 123523-09-1
Category:
Target:
Cat. No.: HY-174635
Target:
Research Areas:
Human IL15RA mRNA encodes the human interleukin 15 receptor subunit alpha (IL15RA) protein, a cytokine receptor that specifically binds interleukin 15 (IL15) with high affinity. IL15RA is reported to enhance cell proliferation and expression of apoptosis inhibitor BCL2L1/BCL2-XL and BCL2.
Cat. No.: HY-10969R
CAS No.: 803712-79-0
Synonyms: GX15-070 Mesylate (Standard)
Obatoclax mesylate (Standard) is the analytical standard of Obatoclax (Mesylate) (HY-10969). This product is intended for research and analytical applications. Obatoclax Mesylate (GX15-070 Mesylate), a BH3 mimetic, is a pan-BCL-2 family proteins inhibitor with a Ki of 220 nM for BCL-2 . Obatoclax Mesylate induces autophagy-dependent cell death and targets cyclin D1 for proteasomal degradation. Obatoclax Mesylate has anti-cancer and broad-spectrum antiparasitic activity .
Cat. No.: HY-183791A
CAS No.: 2243423-32-5
Target:
Ferroptosis Apoptosis Glutathione Peroxidase ACSL Family Reactive Oxygen Species (ROS) Mitochondrial Metabolism Caspase Bcl-2 Family
Research Areas:
Ferroptosis/apoptosis inducer-5 is an orally active inducer of Ferroptosis and Apoptosis. Ferroptosis/apoptosis inducer-5 downregulates GPX4, upregulates ACSL4, promotes ROS production, activates the Caspase cascade, induces Mitochondrial dysfunction, and alters the Bcl-2/Bax balance. Ferroptosis/apoptosis inducer-5 significantly inhibits tumor growth in a pancreatic cancer xenograft mouse model. Ferroptosis/apoptosis inducer-5 can be used for the research of pancreatic cancer .
Cat. No.: HY-184443
CAS No.: 3119834-80-6
Target:
Microtubule/Tubulin Bcl-2 Family Apoptosis MDM-2/p53 Mitochondrial Metabolism Reactive Oxygen Species (ROS)
Research Areas:
Bcl-2-IN-26 is an inhibitor targeting β-tubulin and BCL-2. Bcl-2-IN-26 disrupts the intracellular microtubule network and interferes with cell mitosis, inducing G2/M phase cell cycle arrest. Bcl-2-IN-26 suppresses antiapoptotic BCL-2 function via p53 upregulation, thereby triggering mitochondrial dysfunction, elevated ROS production and robust tumor cell apoptosis. Bcl-2-IN-26 can be used in lung cancer research .
Cat. No.: HY-50907R
CAS No.: 852808-04-9
Research Areas:
ABT-737 (Standard) is the analytical standard of ABT-737 (HY-50907). This product is intended for research and analytical applications. ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-xL and Bcl-w inhibitor with EC50s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research .
Cat. No.: HY-129179S
Synonyms: APG-2575-d8; BCL-2/BCL-xl inhibitor 1-d8
Target:
Research Areas:
Lisaftoclax-d8 is the deuterated-labeled Lisaftoclax (HY-129179). Lisaftoclax is an orally active, selective BCL-2 inhibitor with a Ki of < 0.1 nM against human BCL-2. Lisaftoclax selectively binds to BCL-2, disrupts the BCL-2:BIM complex, and antagonizes the antiapoptotic function of BCL-2. Lisaftoclax induces BAX/BAK-dependent, caspase-mediated apoptosis, upregulates the pro-death proteins BIM and Noxa, and downregulates mitochondrial respiratory function and ATP production. Lisaftoclax can be used in the research of hematological malignancies including chronic lymphocytic leukemia, multiple myeloma, and diffuse large B-cell lymphoma .
Cat. No.: HY-173365
VEGFR-2-IN-67 (Compound 6b) is an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2). Its IC50 values for MDA-231 and MCF-7 cell lines are 5.91 µM and 7.16 µM respectively, and its inhibitory effect on VEGFR-2 is comparable to that of Sorafenib (HY-10201) (IC50 is 53.63 nM). VEGFR-2-IN-67 exerts significant anti-cancer activity through mechanisms such as inducing Apoptosis (the early apoptosis rate reaches 57.20%), arresting the cell cycle at the G1 phase, upregulating pro-apoptotic markers and downregulating Bcl-2. VEGFR-2-IN-67 can be used for research in the field of cancer .
Cat. No.: HY-N14116A
CAS No.: 8000-78-0
Target:
NF-κB NOD-like Receptor (NLR) Glutathione S-transferase Heme Oxygenase (HO) Quinone Reductase Bcl-2 Family Apoptosis Reactive Oxygen Species (ROS) Pyroptosis
Research Areas:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Garlic oil (synthetic) is an orally effective anti-inflammatory, antioxidant, and anticancer agent. Garlic oil (synthetic) inhibits the activation of NF-κB, NFκB2 and NLRP3 inflammasome, and induces the expression of GSTA1, HO-1 and NQO-1. Garlic oil (synthetic) reduces the Bcl-2/Bax protein ratio and activates NNK-induced apoptosis (apoptosis) in lung tissues. Garlic oil (synthetic) attenuates NNK-induced apoptosis in MRC-5 cells and reduces excessive ROS production. Garlic oil (synthetic) alleviates pyroptosis (pyroptosis) and exerts a protective effect against acute lung injury in mice. Garlic oil (synthetic) inhibits lung tumorigenesis in mice and improves small intestinal motility in rats with type 2 diabetes . Garlic oil (synthetic) can be used in research related to acute lung injury, lung cancer, peptic ulcer, type 2 diabetes and hypertension .
Cat. No.: HY-182745
VEGFR-2-IN-85 is a strong VEGFR-2 inhibitor, with an IC50 value of 0.23 μM. VEGFR-2-IN-85 exhibits potent cytotoxic activity against multiple cancer cell lines with minimal toxicity toward normal cells. VEGFR-2-IN-85 also impairs cancer cell migration, likely through modulation of the VEGFR-2/p-Akt pathway. VEGFR-2-IN-85 can induce apoptosis through modulation of Caspase-3, Bax and Bcl-2. VEGFR-2-IN-85 arrests cell cycle at the G2/M phase and has anti-angiogenic activity. VEGFR-2-IN-85 is a targeted radiosensitizer enhancing radiation-induced cytotoxicity. VEGFR-2-IN-85 can be used for research on cancers such as non-small cell lung cancer, breast cancer, and liver cancer .
Cat. No.: HY-N17617
CAS No.: 70238-51-6
Cat. No.: HY-116054
CAS No.: 1314096-68-8
Research Areas:
Ibulocydine is an isobutyrate prodrug of the Cdk inhibitor BMK-Y101 (HY-188159), with oral activity, and exhibits IC50 values of approximately 50 nM against CDK1/CDK2, 530 nM against CDK7/cyclin H/Mat1, and 85 nM against CDK9/cyclin T. Ibulocydine reduces the phosphorylation levels of Rb, nucleolin, and RNA polymerase II CTD Ser-5 and Ser-2, downregulates the expression of Mcl-1, survivin, and XIAP, decreases MMP-9 expression, and lowers the Bcl-2/Bax ratio, activates calpain-mediated Bax cleavage, cytochrome c release, and caspase activation. Ibulocydine induces apoptosis, inhibits the growth of cancer cells and xenografts, enhances the sensitivity of cancer cells to TRAIL and radiotherapy, and blocks cancer cell metastasis. Ibulocydine can be used in research related to various cancers, including hepatocellular carcinoma, triple-negative breast cancer, lung cancer, and colon cancer .
Cat. No.: HY-181015
Research Areas:
α-D-Manp(3→1)-α-D-Manp(2→1)-α-D-Glu (Compound C) is an oligosaccharide. α-D-Manp(3→1)-α-D-Manp(2→1)-α-D-Glu activates the PI3K/AKT signaling pathway. α-D-Manp(3→1)-α-D-Manp(2→1)-α-D-Glu significantly inhibits Apoptosis by regulating the Bcl-2/BAX ratio. α-D-Manp(3→1)-α-D-Manp(2→1)-α-D-Glu shows cytoprotective activity by reducing ROS and LDH levels, decreasing MDA activity, and increasing CAT, SOD, and GSH activities. α-D-Manp(3→1)-α-D-Manp(2→1)-α-D-Glu shows neuroprotective effects and antioxidant capacity .
Cat. No.: HY-184501
CAS No.: 486440-74-8
UE01 is an orally active, selective small-molecule modulator targeting both ULK1/ERK1/2. UE01 activates hULK1 with an EC50 of 695.30 nM and a KD of 114.3 nM for ULK1; it inhibits hERK1 with an IC50 of 179.90 nM and a KD of 114 nM for ERK1; it shows weak binding to ERK2 with a KD of 2.8 mM. UE01 induces the conformational transition of ULK1 from an inactive to an active state, enhances the phosphorylation of ULK1 Ser317 and mAtg13 Ser355, and reduces the phosphorylation of ULK1 Ser757. UE01 competitively occupies the ATP-binding pocket of ERK1, inhibits ERK1 kinase activity, and reduces the activity of the ERK1/2 signaling pathway. UE01 induces complete autophagy flux and apoptosis, upregulates Atg5, Atg7, LC3-II/LC3-I, Bax, cytochrome C (Cyt c), Cleaved-Caspase 3, Cleaved-PARP1 and E-cadherin, downregulates p62, Bcl-2, MMP-2 and MMP-9, reduces the phosphorylation of Exo70 Ser250, and promotes the proteasome-dependent degradation of Cav-1, thereby inhibiting EMT-related phenotypes and extracellular matrix degradation. UE01 can be used in studies related to triple-negative breast cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
